Discovery of a stilbenoid-flavanone hybrid as an antitumor Wnt/β-catenin signaling pathway inhibitor

A series of designed stilbenoid-flavanone hybrids featuring sp³-hybridized C2 and C3 atoms of C-ring was evaluated against colorectal cancers presented compounds 4, 17, and 20 as the most potential compounds among explored compounds. Evaluation of the Anticancer activity spectrum of compounds 4, 17, and 20 against diverse solid tumors presented compounds 17 and 20 with interesting Anticancer spectrum. The potencies of compounds 17 and 20 were assessed in comparison with FDA-approved Anticancer drugs. Compound 17 was the, in general, the most potent showing low micromolar GI₅₀ values that were more potent than the standard FDA-approved drugs against several solid tumors including colon, brain, skin, renal, prostate and breast tumors. Compound 17 was subjected for evaluation against normal cell lines and was subjected to a mechanism study in HCT116 colon Cancer cells which presented it as an inhibitor of Wnt signaling pathway triggering G₂/M cell cycle arrest though activation of p53-p21 pathway as well as intrinsic and extrinsic apoptotic death of colon Cancer cells. Compound 17 might be a candidate for further development against diverse solid tumors including colon Cancer.

Apoptosis; Cell cycle arrest; Colon cancer; Hybrids; Natural products; Stilbenoids, Flavanones; Wnt/β-Catenin signaling.